⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Safety and Efficacy of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: 1-year Analysis of the ENLIGHTEN Study (P10-6.014)

Robert T. Naismith Robert Zivadinov Sarah A. Morrow Ann Bass Ahmed Z. Obeidat Emily Riser Sibyl Wray Massimiliano Cristofanilli Jon Riolo Andrew Thorpe Burhan Chaudhry Kamran Mohiuddin Chun-Yen Cheng John DeLuca

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

This ad hoc analysis describes the efficacy and safety profile of ozanimod over 1 year.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Naismith et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677dba https://doi.org/10.1212/wnl.0000000000204934

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Updated Study Data for Ozanimod in Relapsing Multiple Sclerosis2024
2Real-world Experience With Ozanimod at Two Academic Multiple Sclerosis Centers With Expanded 24-month Data (P4-20.003)Original Research · 2026
3Brain Volume Changes Over 1 Year in Ozanimod-treated Patients with Early-relapsing Multiple Sclerosis: An Interim Analysis of the ENLIGHTEN Study (P11-6.017)2024 · 2 citations
4Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial (P2-6.007)2024
5Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosisHuman Clinical Trial · 2026 · 4 citations